X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with FDC LTD. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs FDC LTD. - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA FDC LTD. ELDER PHARMA/
FDC LTD.
 
P/E (TTM) x -0.2 28.7 - View Chart
P/BV x 0.1 6.0 1.7% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ELDER PHARMA   FDC LTD.
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
FDC LTD.
Mar-14
ELDER PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs380144 264.8%   
Low Rs18879 238.0%   
Sales per share (Unadj.) Rs491.247.6 1,032.7%  
Earnings per share (Unadj.) Rs-3.27.6 -41.8%  
Cash flow per share (Unadj.) Rs14.49.0 159.9%  
Dividends per share (Unadj.) Rs02.25 0.0%  
Dividend yield (eoy) %02.0 0.0%  
Book value per share (Unadj.) Rs376.547.5 792.1%  
Shares outstanding (eoy) m20.54177.83 11.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.62.3 24.7%   
Avg P/E ratio x-89.314.6 -610.5%  
P/CF ratio (eoy) x19.712.3 159.6%  
Price / Book Value ratio x0.82.3 32.2%  
Dividend payout %029.6 0.0%   
Avg Mkt Cap Rs m5,83319,784 29.5%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1791,221 178.5%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m10,0898,459 119.3%  
Other income Rs m257394 65.2%   
Total revenues Rs m10,3468,852 116.9%   
Gross profit Rs m-7922,070 -38.3%  
Depreciation Rs m361249 145.0%   
Interest Rs m2,75631 8,888.4%   
Profit before tax Rs m-3,6532,184 -167.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-225 0.0%   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125606 20.7%   
Profit after tax Rs m-651,353 -4.8%  
Gross profit margin %-7.824.5 -32.1%  
Effective tax rate %-3.427.7 -12.4%   
Net profit margin %-0.616.0 -4.0%  
BALANCE SHEET DATA
Current assets Rs m9,2404,355 212.2%   
Current liabilities Rs m9,9981,792 557.9%   
Net working cap to sales %-7.530.3 -24.8%  
Current ratio x0.92.4 38.0%  
Inventory Days Days4644 104.2%  
Debtors Days Days6025 243.0%  
Net fixed assets Rs m10,1243,025 334.7%   
Share capital Rs m206179 115.2%   
"Free" reserves Rs m5,5828,243 67.7%   
Net worth Rs m7,7348,453 91.5%   
Long term debt Rs m4,88911 45,691.6%   
Total assets Rs m22,88210,557 216.7%  
Interest coverage x-0.371.4 -0.5%   
Debt to equity ratio x0.60 49,942.6%  
Sales to assets ratio x0.40.8 55.0%   
Return on assets %11.813.1 89.7%  
Return on equity %-0.816.0 -5.3%  
Return on capital %22.323.5 94.9%  
Exports to sales %3.013.3 22.8%   
Imports to sales %0.43.3 12.8%   
Exports (fob) Rs m3071,126 27.2%   
Imports (cif) Rs m43283 15.2%   
Fx inflow Rs m3071,146 26.8%   
Fx outflow Rs m125355 35.3%   
Net fx Rs m181791 22.9%   
CASH FLOW
From Operations Rs m11,7541,485 791.6%  
From Investments Rs m-561-620 90.5%  
From Financial Activity Rs m-6,762-753 898.6%  
Net Cashflow Rs m4,432113 3,928.8%  

Share Holding

Indian Promoters % 39.6 68.9 57.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 4.7 159.6%  
FIIs % 16.8 7.5 224.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 19.0 190.0%  
Shareholders   16,479 23,730 69.4%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT LTD.  GSK PHARMA  PANACEA BIOTECH  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - SUVEN LIFE COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS